Cargando…
Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, is approved in the European Union for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients refractory or contraindicated to or intolerant of other systemic therapies. OBJECTIVES: The APPRECIATE study assessed ap...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909071/ https://www.ncbi.nlm.nih.gov/pubmed/36777399 http://dx.doi.org/10.1177/20406223231152785 |
_version_ | 1784884490714218496 |
---|---|
author | Jonak, Constanze Göttfried, Isolde Perl-Convalexius, Sylvia Gruber, Barbara Schütz-Bergmayr, Martina Vujic, Igor Weger, Wolfgang Schicher, Nikolaus Semlin, Lydia Hemetsberger, Margit Cordey, Myriam Sator, Paul |
author_facet | Jonak, Constanze Göttfried, Isolde Perl-Convalexius, Sylvia Gruber, Barbara Schütz-Bergmayr, Martina Vujic, Igor Weger, Wolfgang Schicher, Nikolaus Semlin, Lydia Hemetsberger, Margit Cordey, Myriam Sator, Paul |
author_sort | Jonak, Constanze |
collection | PubMed |
description | BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, is approved in the European Union for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients refractory or contraindicated to or intolerant of other systemic therapies. OBJECTIVES: The APPRECIATE study assessed apremilast use in real-world practice and its clinical value to physicians and patients. APPRECIATE was a multinational, observational, retrospective, cross-sectional study. METHODS: Apremilast effectiveness at 6 (±1) months was assessed on the basis of psoriasis severity and health-related quality-of-life scores and treatment satisfaction using physician/patient-reported outcomes, respectively. We report the Austrian cohort of 72 patients. RESULTS: At 6 (±1) months, three-quarters of patients remained on apremilast, while physicians and patients reported treatment benefits across all psoriasis symptoms and manifestations. Of patients, the majority were satisfied with their treatment and achieved treatment goals considered most relevant. Patients’ and physicians’ perceptions of treatment effectiveness were aligned, and health-related quality-of-life scores indicated an improvement in the majority of patients. Apremilast tolerability was consistent with the known safety profile. CONCLUSIONS: Among psoriasis patients receiving apremilast in Austria, improvement in clinical outcomes were observed and satisfaction with apremilast treatment among patients and physicians was high. REGISTRATION: ClinicalTrials.gov NCT02740218 |
format | Online Article Text |
id | pubmed-9909071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-99090712023-02-10 Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study Jonak, Constanze Göttfried, Isolde Perl-Convalexius, Sylvia Gruber, Barbara Schütz-Bergmayr, Martina Vujic, Igor Weger, Wolfgang Schicher, Nikolaus Semlin, Lydia Hemetsberger, Margit Cordey, Myriam Sator, Paul Ther Adv Chronic Dis Original Research BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, is approved in the European Union for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients refractory or contraindicated to or intolerant of other systemic therapies. OBJECTIVES: The APPRECIATE study assessed apremilast use in real-world practice and its clinical value to physicians and patients. APPRECIATE was a multinational, observational, retrospective, cross-sectional study. METHODS: Apremilast effectiveness at 6 (±1) months was assessed on the basis of psoriasis severity and health-related quality-of-life scores and treatment satisfaction using physician/patient-reported outcomes, respectively. We report the Austrian cohort of 72 patients. RESULTS: At 6 (±1) months, three-quarters of patients remained on apremilast, while physicians and patients reported treatment benefits across all psoriasis symptoms and manifestations. Of patients, the majority were satisfied with their treatment and achieved treatment goals considered most relevant. Patients’ and physicians’ perceptions of treatment effectiveness were aligned, and health-related quality-of-life scores indicated an improvement in the majority of patients. Apremilast tolerability was consistent with the known safety profile. CONCLUSIONS: Among psoriasis patients receiving apremilast in Austria, improvement in clinical outcomes were observed and satisfaction with apremilast treatment among patients and physicians was high. REGISTRATION: ClinicalTrials.gov NCT02740218 SAGE Publications 2023-02-07 /pmc/articles/PMC9909071/ /pubmed/36777399 http://dx.doi.org/10.1177/20406223231152785 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Jonak, Constanze Göttfried, Isolde Perl-Convalexius, Sylvia Gruber, Barbara Schütz-Bergmayr, Martina Vujic, Igor Weger, Wolfgang Schicher, Nikolaus Semlin, Lydia Hemetsberger, Margit Cordey, Myriam Sator, Paul Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study |
title | Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study |
title_full | Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study |
title_fullStr | Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study |
title_full_unstemmed | Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study |
title_short | Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study |
title_sort | characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in austria – results the appreciate study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909071/ https://www.ncbi.nlm.nih.gov/pubmed/36777399 http://dx.doi.org/10.1177/20406223231152785 |
work_keys_str_mv | AT jonakconstanze characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy AT gottfriedisolde characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy AT perlconvalexiussylvia characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy AT gruberbarbara characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy AT schutzbergmayrmartina characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy AT vujicigor characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy AT wegerwolfgang characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy AT schichernikolaus characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy AT semlinlydia characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy AT hemetsbergermargit characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy AT cordeymyriam characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy AT satorpaul characteristicsandoutcomesofpatientswithpsoriasistreatedwithapremilastintherealworldinaustriaresultstheappreciatestudy |